| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NM.3850 |
| P698 | PubMed publication ID | 25894828 |
| P50 | author | Yong Gang Yue | Q87154542 |
| Kyoung-Mee Kim | Q88377030 | ||
| P2093 | author name string | Jian Wang | |
| Kun Yu | |||
| Patrick Tan | |||
| Ronghua Chen | |||
| Christoph Reinhard | |||
| Andrey Loboda | |||
| Mark Ayers | |||
| Michael Nebozhyn | |||
| Sin-Ho Jung | |||
| Insuk Sohn | |||
| Se Hoon Park | |||
| Jason C Ting | |||
| Sung Kim | |||
| Jason Gang Jin | |||
| Jeeyun Lee | |||
| Seung Tae Kim | |||
| Won Ki Kang | |||
| Joon Ho Lee | |||
| In-Gu Do | |||
| Jiangang Liu | |||
| Razvan Cristescu | |||
| Jae Moon Bae | |||
| Min Gew Choi | |||
| Tae Sung Sohn | |||
| Xiang S Ye | |||
| Amit Aggarwal | |||
| Shawn Liu | |||
| James Hardwick | |||
| Swee Seong Wong | |||
| Jake Fu | |||
| Dai Hongyue | |||
| Lara Gong | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| HER2 testing in gastric cancer: a practical approach | Q28256814 | ||
| Integrated genomic characterization of endometrial carcinoma | Q28289962 | ||
| Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma | Q79770794 | ||
| Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma | Q81383354 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| Molecular classification of gastric cancer: a new paradigm | Q30500375 | ||
| PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data | Q33511182 | ||
| EMT is the dominant program in human colon cancer | Q33798739 | ||
| Gene enrichment profiles reveal T-cell development, differentiation, and lineage-specific transcription factors including ZBTB25 as a novel NF-AT repressor | Q33985141 | ||
| Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition | Q34522228 | ||
| A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients | Q34557719 | ||
| Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial | Q34634440 | ||
| Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial | Q34634936 | ||
| Comparison of global gene expression of gastric cardia and noncardia cancers from a high-risk population in china | Q34744703 | ||
| Gene expression signature-based prognostic risk score in gastric cancer | Q34802936 | ||
| Large-scale characterization of DNA methylation changes in human gastric carcinomas with and without metastasis | Q35023839 | ||
| Emerging landscape of oncogenic signatures across human cancers | Q35058708 | ||
| Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling | Q35070183 | ||
| Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery | Q35112054 | ||
| Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy | Q35154288 | ||
| Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma | Q35166408 | ||
| Targeted therapies for breast cancer | Q35372584 | ||
| Variation in gene expression patterns in human gastric cancers | Q35670324 | ||
| A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets | Q35878807 | ||
| Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies | Q36660664 | ||
| Oncogenic pathway combinations predict clinical prognosis in gastric cancer. | Q37357165 | ||
| Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma | Q37692604 | ||
| Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. | Q38307191 | ||
| Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil | Q38490073 | ||
| Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer | Q38997289 | ||
| Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing | Q39096557 | ||
| Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. | Q40687159 | ||
| Methylation subtypes and large-scale epigenetic alterations in gastric cancer | Q43936243 | ||
| Instabilotyping reveals unique mutational spectra in microsatellite-unstable gastric cancers. | Q44049883 | ||
| Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma | Q45376744 | ||
| An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach | Q46649725 | ||
| Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer | Q46898080 | ||
| The impact of microsatellite instability on the molecular phenotype of colorectal tumors | Q47703666 | ||
| A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. | Q52014045 | ||
| Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer | Q56601042 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 449-456 | |
| P577 | publication date | 2015-04-20 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes | |
| P478 | volume | 21 |
| Q92654797 | A 21‑gene Support Vector Machine classifier and a 10‑gene risk score system constructed for patients with gastric cancer |
| Q38738541 | A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets |
| Q57585255 | A GWAS on Helicobacter pylori strains points to genetic variants associated with gastric cancer risk |
| Q90221059 | A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling |
| Q64286762 | A genomewide transcriptomic approach identifies a novel gene expression signature for the detection of lymph node metastasis in patients with early stage gastric cancer |
| Q37268013 | A long non-coding RNA signature to improve prognosis prediction of gastric cancer |
| Q93031588 | A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study |
| Q64914877 | A novel YAP1/SLC35B4 regulatory axis contributes to proliferation and progression of gastric carcinoma. |
| Q37688244 | A novel gene expression-based prognostic scoring system to predict survival in gastric cancer |
| Q92835317 | A novel risk score model for stomach adenocarcinoma based on the expression levels of 10 genes |
| Q55493174 | A prospective study on the changes and clinical significance of pre-operative and post-operative circulating tumor cells in resectable gastric cancer. |
| Q40824215 | A protein and mRNA expression-based classification of gastric cancer |
| Q52727768 | A proteomic landscape of diffuse-type gastric cancer. |
| Q64057596 | A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I-III colon cancer |
| Q64103643 | A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors |
| Q92450454 | A targeted proteomics approach reveals a serum protein signature as diagnostic biomarker for resectable gastric cancer |
| Q89868771 | A transcriptional co-expression network-based approach to identify prognostic biomarkers in gastric carcinoma |
| Q33577624 | A unified model of the hierarchical and stochastic theories of gastric cancer |
| Q91657979 | ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer |
| Q58100576 | ASO Author Reflections: Consideration of a Modified Classification System for Gastric Cancer Based on Lauren Subtypes |
| Q37716485 | Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion |
| Q47113548 | Actionable gene-based classification toward precision medicine in gastric cancer. |
| Q39091817 | Advanced gastric adenocarcinoma: optimizing therapy options. |
| Q38697255 | Advances in the Management of Gastric and Gastroesophageal Cancers. |
| Q51213021 | Amplified 7q21-22 gene MCM7 and its intronic miR-25 suppress COL1A2 associated genes to sustain intestinal gastric cancer features. |
| Q104459144 | An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer |
| Q91655530 | An immune-related gene signature predicts prognosis of gastric cancer |
| Q99558033 | An integrated classifier improves prognostic accuracy in non-metastatic gastric cancer |
| Q38578404 | Angiogenesis inhibitors in gastric and gastroesophageal junction cancer |
| Q39067386 | Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review |
| Q92972185 | Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications |
| Q31109151 | Assessing the clinical utility of genomic expression data across human cancers |
| Q92862792 | Association Between the Microsatellite Instability Status and the Efficacy of Postoperative Adjuvant Chemoradiotherapy in Patients With Gastric Cancer |
| Q28066550 | Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers |
| Q90685811 | Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient |
| Q90385469 | Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine |
| Q38575013 | Biomarkers and novel agents in esophago-gastric cancer: are we making progress? |
| Q39007277 | CAsubtype: An R Package to Identify Gene Sets Predictive of Cancer Subtypes and Clinical Outcomes |
| Q61448598 | CDH1 somatic alterations in Mexican patients with diffuse and mixed sporadic gastric cancer |
| Q40254778 | COL1A2 is a Novel Biomarker to Improve Clinical Prediction in Human Gastric Cancer: Integrating Bioinformatics and Meta-Analysis |
| Q52565789 | CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer. |
| Q54233300 | Chilean Gastric Cancer Task Force: A study protocol to obtain a clinical and molecular classification of a cohort of gastric cancer patients. |
| Q39255073 | Chromosomal Instability in Gastric Cancer Biology. |
| Q90196913 | Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer |
| Q96167110 | Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis |
| Q100955017 | Classification of gastric cancers based on immunogenomic profiling |
| Q90620231 | Clinical Implementation of Precision Medicine in Gastric Cancer |
| Q92384134 | Clinical Implications of Microsatellite Instability in Early Gastric Cancer |
| Q92492093 | Clinical Outcomes of Metachronous Gastric Cancer after Endoscopic Resection for Early Gastric Cancer |
| Q64115689 | Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers |
| Q54938715 | Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. |
| Q90321333 | Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor-node-metastasis staging system and beyond |
| Q38958539 | Clinical application of early gastric carcinoma with lymphoid stroma based on lymph node metastasis status |
| Q48140624 | Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency. |
| Q88801590 | Clinical impact of molecular classifications in gastric cancer |
| Q33922534 | Clinical impact of tumour biology in the management of gastroesophageal cancer |
| Q92712432 | Clinical relevance of somatic mutations in main driver genes detected in gastric cancer patients by next-generation DNA sequencing |
| Q33709895 | Clinical utility of circulating cell-free Epstein-Barr virus DNA in patients with gastric cancer |
| Q33688662 | Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients |
| Q39411073 | Clonality analysis of synchronous gastroesophageal junction carcinoma and distal gastric cancer by whole-exome sequencing. |
| Q48134310 | Combination of TNM staging and pathway based risk score models in patients with gastric cancer. |
| Q88984924 | Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma |
| Q52603962 | Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. |
| Q64245400 | Comparison between 7th and 8th edition of AJCC TNM staging system for gastric cancer: old problems and new perspectives |
| Q92005709 | Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma |
| Q33888813 | Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer |
| Q37536970 | Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. |
| Q59356808 | Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer |
| Q36670779 | Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis |
| Q27853392 | Comprehensive mutation profiling of mucinous gastric carcinoma |
| Q61443106 | Comprehensive profiling of JMJD3 in gastric cancer and its influence on patient survival |
| Q47145152 | Correlation between MEK signature and Ras gene alteration in advanced gastric cancer |
| Q94602743 | Could CTSK and COL4A2 be specific biomarkers of poor prognosis for patients with gastric cancer in Asia?-a microarray analysis based on regional population |
| Q58801774 | Cross-Database Analysis Reveals Sensitive Biomarkers for Combined Therapy for ERBB2+ Gastric Cancer |
| Q92351826 | Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications |
| Q42371631 | Development of mesenchymal subtype gene signature for clinical application in gastric cancer |
| Q91816312 | Differential effects, on oncogenic pathway signalling, by derivatives of the HNF4 α inhibitor BI6015 |
| Q41242612 | Differentially Expressed lncRNAs in Gastric Cancer Patients: A Potential Biomarker for Gastric Cancer Prognosis |
| Q98949018 | Digital image analysis in pathologist-selected regions of interest predicts survival more accurately than whole-slide analysis: a direct comparison study in 153 gastric carcinomas |
| Q57212546 | Discovery and Validation of Salivary Extracellular RNA Biomarkers for Noninvasive Detection of Gastric Cancer |
| Q91904026 | Discovery and validation of methylated-differentially expressed genes in Helicobacter pylori-induced gastric cancer |
| Q58741167 | Dissecting cancer heterogeneity based on dimension reduction of transcriptomic profiles using extreme learning machines |
| Q93175115 | Dissection of gastric cancer heterogeneity for precision oncology |
| Q46495665 | Distal Esophageal Adenocarcinoma and Gastric Adenocarcinoma: Time for a Shared Research Agenda. |
| Q90480511 | Distinct expression and prognostic values of the replication protein A family in gastric cancer |
| Q55117181 | Distinct molecular subtypes of gastric cancer: from Laurén to molecular pathology. |
| Q41279692 | Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment |
| Q89807818 | Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances |
| Q92431484 | Dynamic characterization of intestinal metaplasia in the gastric corpus mucosa of Atp4a-deficient mice |
| Q51577533 | Dysregulated Wnt signalling and recurrent mutations of the tumour suppressor RNF43 in early gastric carcinogenesis. |
| Q56968100 | EBV infection determines the immune hallmarks of plasmablastic lymphoma |
| Q55082025 | EBV⁺ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8⁺ Intratumoral Lymphocytes. |
| Q36069955 | EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus |
| Q41702599 | Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer. |
| Q91868485 | Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis |
| Q37377194 | Elevated Expression of Calpain-4 Predicts Poor Prognosis in Patients with Gastric Cancer after Gastrectomy |
| Q33844651 | Elevated PRC1 in gastric carcinoma exerts oncogenic function and is targeted by piperlongumine in a p53-dependent manner |
| Q57111080 | Emerging Therapies in the Management of Advanced-Stage Gastric Cancer |
| Q26745525 | Emerging molecular classifications and therapeutic implications for gastric cancer |
| Q38947310 | Emerging power of proteomics for delineation of intrinsic tumor subtypes and resistance mechanisms to anti-cancer therapies |
| Q64075578 | Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults |
| Q63392570 | Epigenetic Alterations in Stomach Cancer: Implications for Diet and Nutrition |
| Q37665344 | Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. |
| Q37315416 | Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity |
| Q64288065 | Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer |
| Q92063533 | Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology |
| Q36633405 | Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. |
| Q55282987 | Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. |
| Q89953432 | Ethnicity-related differences in tumor immunity: a new possible explanation for gastric cancer prognostic variability? |
| Q97540776 | Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma |
| Q26800355 | Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine |
| Q54002230 | Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. |
| Q26741242 | Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature |
| Q90600978 | Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1 |
| Q91640393 | Expression and Clinical Relevance of SOX9 in Gastric Cancer |
| Q40733626 | FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival |
| Q93087677 | FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape |
| Q64286913 | Fatty acid 2-hydroxylation inhibits tumor growth and increases sensitivity to cisplatin in gastric cancer |
| Q92605053 | Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis |
| Q92615751 | Feedback regulation between phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 and transforming growth factor β1 and prognostic value in gastric cancer |
| Q64117305 | Five-long non-coding RNA risk score system for the effective prediction of gastric cancer patient survival |
| Q54238201 | Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. |
| Q91596559 | Function of fibroblast growth factor 2 in gastric cancer occurrence and prognosis |
| Q38630652 | Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression. |
| Q58551710 | Gastric Cancer Cell Lines Have Different -Regulated Expression Patterns but Share a Common Core of Altered Genes |
| Q37673604 | Gastric Cancer Genomics: Advances and Future Directions. |
| Q90446444 | Gastric Cancer in Young Adults: A Different Clinical Entity from Carcinogenesis to Prognosis |
| Q33600457 | Gastric Cancer in the Era of Precision Medicine |
| Q90161872 | Gastric Cancer with Radiographically Occult Metastatic Disease: Biology, Challenges, and Diagnostic Approaches |
| Q39343374 | Gastric adenocarcinoma. |
| Q99622843 | Gastric cancer |
| Q30248452 | Gastric cancer - clinical and epidemiological aspects. |
| Q89286821 | Gastric cancer surgery |
| Q50168318 | Gastric cancer: Basic aspects. |
| Q89983819 | Gastric cancer: genome damaged by bugs |
| Q47607822 | Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics |
| Q48127873 | Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes |
| Q88189128 | Gastrin and Gastric Cancer |
| Q104073697 | Gastrointestinal adenocarcinoma analysis identifies promoter methylation-based cancer subtypes and signatures |
| Q52565231 | Gene expression profiles for a prognostic immunoscore in gastric cancer. |
| Q38585708 | Gene mutations in gastric cancer: a review of recent next-generation sequencing studies |
| Q47106128 | Gene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencing |
| Q58791819 | Gene regulatory network construction identified NFYA as a diffuse subtype-specific prognostic factor in gastric cancer |
| Q58795968 | GeneExpressScore Signature: a robust prognostic and predictive classifier in gastric cancer |
| Q46668930 | Genes co-amplified with ERBB2 or MET as novel potential cancer-promoting genes in gastric cancer |
| Q47584566 | Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. |
| Q99551759 | Genetic profiling of somatic alterations by Oncomine Focus Assay in Korean patients with advanced gastric cancer |
| Q39453164 | Genetic variants in gastric cancer: Risks and clinical implications |
| Q58565340 | Genome-scale analysis identifies SERPINE1 and SPARC as diagnostic and prognostic biomarkers in gastric cancer |
| Q98613437 | Genome-wide identification of CpG island methylator phenotype related gene signature as a novel prognostic biomarker of gastric cancer |
| Q49643762 | Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features |
| Q52560262 | Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab. |
| Q26751062 | Genomic alterations and molecular subtypes of gastric cancers in Asians |
| Q38651789 | Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing |
| Q103804153 | Genomic and transcriptomic alterations associated with drug vulnerabilities and prognosis in adenocarcinoma at the gastroesophageal junction |
| Q38779428 | Genomic pathobiology of gastric carcinoma |
| Q98735788 | Genomics Score Based on Genome-Wide Network Analysis for Prediction of Survival in Gastric Cancer: A Novel Prognostic Signature |
| Q38826577 | Genomics Study of Gastric Cancer and Its Molecular Subtypes. |
| Q47232401 | Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer - Early Results from the COMPASS Trial. |
| Q89162894 | Germline genetic variants were interactively associated with somatic alterations in gastric cancer |
| Q38813532 | Global chemotherapy development for gastric cancer |
| Q64929513 | Global transcriptomic analysis identifies SERPINE1 as a prognostic biomarker associated with epithelial-to-mesenchymal transition in gastric cancer. |
| Q47110681 | Heated intraperitoneal chemotherapy and gastrectomy for gastric cancer in the U.S.: the time is now. |
| Q36116464 | Helicobacter pylori, Cancer, and the Gastric Microbiota |
| Q39104065 | Helicobacter pylori-Mediated Genetic Instability and Gastric Carcinogenesis |
| Q93118236 | Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features |
| Q43824474 | High Intratumoral Expression of Tetranectin Associates with Poor Prognosis of Patients with Gastric Cancer after Gastrectomy |
| Q93078479 | High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study |
| Q92382465 | High expression of fibronectin 1 indicates poor prognosis in gastric cancer |
| Q38864582 | High-risk and low-risk gastric cancer areas in Italy and its association with microsatellite instability |
| Q91604017 | Histo- and immunohistochemistry-based estimation of the TCGA and ACRG molecular subtypes for gastric carcinoma and their prognostic significance: A single-institution study |
| Q47577423 | Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity |
| Q39312802 | How to stomach an epigenetic insult: the gastric cancer epigenome |
| Q50125239 | Hyperactive gp130/STAT3-driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development. |
| Q37747546 | IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. |
| Q37725411 | IKKε and TBK1 expression in gastric cancer |
| Q64076264 | IRF6 Is Directly Regulated by ZEB1 and ELF3, and Predicts a Favorable Prognosis in Gastric Cancer |
| Q91711299 | Identification of Subtype-Specific Three-Gene Signature for Prognostic Prediction in Diffuse Type Gastric Cancer |
| Q94475919 | Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma |
| Q48026879 | Identification of a prognostic 5-Gene expression signature for gastric cancer |
| Q90480845 | Identification of circulating tumor DNA using a targeted 545-gene next generation sequencing panel in patients with gastric cancer |
| Q55002251 | Identification of genomic aberrations associated with lymph node metastasis in diffuse-type gastric cancer. |
| Q55295718 | Identification of hub genes with prognostic values in gastric cancer by bioinformatics analysis. |
| Q40562647 | Identifying Reproducible Molecular Biomarkers for Gastric Cancer Metastasis with the Aid of Recurrence Information |
| Q64123203 | Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer |
| Q57068038 | Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial |
| Q28071836 | Immunological battlefield in gastric cancer and role of immunotherapies |
| Q38738652 | Immunotherapy for gastric cancers: emerging role and future perspectives |
| Q50160878 | Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2-positive gastric cancer patients |
| Q61799696 | Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers |
| Q92713103 | Implications of clinical research on adjuvant chemotherapy for gastric cancer: Where to go next? |
| Q55517851 | Improvements to the gastric cancer tumor-node-metastasis staging system based on computer-aided unsupervised clustering. |
| Q38882545 | Increased RhoA Activity Predicts Worse Overall Survival in Patients Undergoing Surgical Resection for Lauren Diffuse-Type Gastric Adenocarcinoma |
| Q37687760 | Increased gene expression noise in human cancers is correlated with low p53 and immune activities as well as late stage cancer |
| Q52990124 | Incremental diagnostic utility of gastric distension FDG PET/CT. |
| Q26748123 | Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways |
| Q37543800 | Integrated Analysis Identifies Molecular Signatures and Specific Prognostic Factors for Different Gastric Cancer Subtypes |
| Q94465919 | Integrated Analysis Identifies an Immune-Based Prognostic Signature for the Mesenchymal Identity in Gastric Cancer |
| Q53193874 | Integrated analysis identified an intestinal-like and a diffuse-like gene sets that predict gastric cancer outcome. |
| Q64063438 | Integrated analysis reveals potential long non-coding RNA biomarkers and their potential biological functions for disease free survival in gastric cancer patients |
| Q92354829 | Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer |
| Q89601287 | Integrated characterisation of cancer genes identifies key molecular biomarkers in stomach adenocarcinoma |
| Q100992474 | Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells |
| Q92841176 | Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines |
| Q53385547 | Intratumoral heterogeneity in gastric cancer: a new challenge to face. |
| Q89715762 | Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched |
| Q40496901 | Juxtaposed genes in 7q21-22 amplicon contribute for two major gastric cancer sub-Types by mutual exclusive expression |
| Q37330144 | KIF2A Overexpression and Its Association with Clinicopathologic Characteristics and Poor Prognoses in Patients with Gastric Cancer. |
| Q47586172 | KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status |
| Q64108587 | KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study |
| Q64076485 | Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach |
| Q58582704 | LASSO‑based Cox‑PH model identifies an 11‑lncRNA signature for prognosis prediction in gastric cancer |
| Q64059672 | LUADpp: an effective prediction model on prognosis of lung adenocarcinomas based on somatic mutational features |
| Q58772571 | Landscape of somatic mutations in gastric cancer assessed using next-generation sequencing analysis |
| Q38985315 | Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma |
| Q38647893 | Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry |
| Q91979148 | LncRNA MAGI2-AS3 Is Regulated by BRD4 and Promotes Gastric Cancer Progression via Maintaining ZEB1 Overexpression by Sponging miR-141/200a |
| Q93101582 | LncRNA MIR4435-2HG targets desmoplakin and promotes growth and metastasis of gastric cancer by activating Wnt/β-catenin signaling |
| Q91705770 | LncRNA NORAD Promotes Proliferation And Inhibits Apoptosis Of Gastric Cancer By Regulating miR-214/Akt/mTOR Axis |
| Q88506860 | LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer |
| Q93198724 | LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway |
| Q57151262 | Long non-coding RNA CCAL/miR-149/FOXM1 axis promotes metastasis in gastric cancer |
| Q64264163 | Long noncoding RNA regulates tumor cell proliferation and invasion by epithelial-mesenchymal transition in gastric cancer |
| Q55402889 | Low scavenger receptor class B type I expression is associated with gastric adenocarcinoma tumor aggressiveness. |
| Q58555650 | Luteolin exerts an anticancer effect on gastric cancer cells through multiple signaling pathways and regulating miRNAs |
| Q37536613 | MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis |
| Q58553420 | MEK Inhibitor Reverses Metaplasia and Allows Re-emergence of Normal Lineages in Helicobacter pylori-infected Gerbils |
| Q89701164 | MFAP2 is overexpressed in gastric cancer and promotes motility via the MFAP2/integrin α5β1/FAK/ERK pathway |
| Q93063710 | Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry |
| Q90622487 | Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening |
| Q47312688 | Medical management of gastric cancer: a 2017 update |
| Q47106713 | MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines |
| Q47593232 | Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. |
| Q58700608 | MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2) |
| Q36326147 | Micronutrients: A double-edged sword in microbial-induced gastric carcinogenesis |
| Q91897101 | Microsatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer |
| Q56889396 | Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches |
| Q38895750 | Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade |
| Q92510487 | Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response |
| Q55437773 | Modification of the TNM Staging System for Stage II/III Gastric Cancer Based on a Prognostic Single Patient Classifier Algorithm. |
| Q55025461 | Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets. |
| Q91708849 | Molecular Classification of Gastric Adenocarcinoma |
| Q92663296 | Molecular Classification of Gastric Cancer among Alaska Native People |
| Q26779725 | Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives |
| Q37710556 | Molecular Testing for Gastrointestinal Cancer. |
| Q55654316 | Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. |
| Q26783806 | Molecular classification and prediction in gastric cancer |
| Q42283228 | Molecular classification of esophagogastric junction carcinoma correlated with prognosis |
| Q33696201 | Molecular classifications of gastric cancers: Novel insights and possible future applications |
| Q38794033 | Molecular key to understand the gastric cancer biology in elderly patients-The role of microsatellite instability |
| Q33895591 | Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature |
| Q37484437 | Molecular mechanisms of gastric cancer initiation and progression by Helicobacter pylori. |
| Q55448998 | Molecular profiling and sequential somatic mutation shift in hypermutator tumours harbouring POLE mutations. |
| Q39235977 | Molecular subtypes in cancers of the gastrointestinal tract |
| Q90198316 | Molecular subtyping of gastric cancer with respect to the growth pattern of lymph-node metastases |
| Q38772049 | Monoclonal antibodies for treating gastric cancer: promises and pitfalls |
| Q37664258 | Mouse models for gastric cancer: Matching models to biological questions. |
| Q41213684 | Moving molecular subtypes to the clinic in gastric cancer |
| Q92571327 | Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response |
| Q57462245 | Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease-Associated Colorectal Cancers |
| Q60916561 | Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer |
| Q64112592 | NPTX1 promotes metastasis via integrin/FAK signaling in gastric cancer |
| Q55077233 | NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. |
| Q91942835 | Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for Gastric Cancer |
| Q92512158 | Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification |
| Q42090072 | New Biology to New Treatment of Helicobacter pylori-Induced Gastric Cancer |
| Q38759129 | New agents on the horizon in gastric cancer |
| Q59136693 | New drug developments in metastatic gastric cancer |
| Q55527185 | New therapeutic options opened by the molecular classification of gastric cancer. |
| Q64990976 | Next-generation sequencing and biomarkers for gastric cancer: what is the future? |
| Q47323830 | Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab. |
| Q26785700 | Noncoding Genomics in Gastric Cancer and the Gastric Precancerous Cascade: Pathogenesis and Biomarkers |
| Q52599496 | Novel Systemic Therapies for Advanced Gastric Cancer. |
| Q38556435 | Novel biomarkers for the identification and targeted therapy of gastric cancer |
| Q26765208 | Novel targets in the treatment of advanced gastric cancer: a perspective review |
| Q97520401 | Observational cohort study of clinical outcome in Epstein-Barr virus associated gastric cancer patients |
| Q38816897 | Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? |
| Q64934996 | Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination. |
| Q52720624 | Outlooks on Epstein-Barr virus associated gastric cancer. |
| Q64983568 | PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer. |
| Q47157362 | PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer |
| Q91729236 | PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin |
| Q39104058 | Pathogenesis of Gastric Cancer: Genetics and Molecular Classification. |
| Q54982215 | Pathway- and clinical-factor-based risk model predicts the prognosis of patients with gastric cancer. |
| Q36413247 | Patient-derived cell models as preclinical tools for genome-directed targeted therapy |
| Q47167566 | Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer |
| Q94564081 | Perineural Invasion and Postoperative Adjuvant Chemotherapy Efficacy in Patients With Gastric Cancer |
| Q64064533 | Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions |
| Q38842137 | Personalised Treatment in Gastric Cancer: Myth or Reality? |
| Q54052500 | Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. |
| Q59330022 | Personalized risk assessment for dynamic transition of gastric neoplasms |
| Q44288144 | Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer |
| Q91788788 | Phosphoglucose isomerase gene expression as a prognostic biomarker of gastric cancer |
| Q89495545 | Pizotifen inhibits the proliferation and invasion of gastric cancer cells |
| Q61811918 | Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer |
| Q36234652 | Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas |
| Q90064455 | Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study |
| Q38824375 | Potentially Curable Cancers of the Esophagus and Stomach. |
| Q94465339 | Precision Medicine in Non Communicable Diseases |
| Q99708836 | Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress |
| Q88136015 | Precision medicine in the adjuvant treatment of gastric cancer |
| Q88136013 | Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis |
| Q42378389 | Profiling cancer-associated genetic alterations and molecular classification of cancer in Korean gastric cancer patients. |
| Q37342600 | Prognostic Importance of Cell Cycle Regulators Cyclin D1 (CCND1) and Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B/p27) in Sporadic Gastric Cancers. |
| Q88177642 | Prognostic Value of Perineural Invasion in Resected Gastric Cancer Patients According to Lauren Histotype |
| Q90257564 | Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from t |
| Q92801850 | Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability |
| Q57167306 | Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer |
| Q37706604 | Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability |
| Q47143363 | Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection |
| Q64052649 | Progress and challenges in HER2-positive gastroesophageal adenocarcinoma |
| Q55603677 | Proposed Molecular and miRNA Classification of Gastric Cancer. |
| Q92132547 | RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis |
| Q101051347 | RUNX3 methylation drives hypoxia-induced cell proliferation and antiapoptosis in early tumorigenesis |
| Q53686273 | Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. |
| Q38940560 | Recapitulating Human Gastric Cancer Pathogenesis: Experimental Models of Gastric Cancer |
| Q64064673 | Recent advances in gastric cancer early diagnosis |
| Q64912862 | Recent advances in the management of gastric adenocarcinoma patients. |
| Q37687784 | Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm |
| Q47110810 | Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer |
| Q48569564 | Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. |
| Q33657952 | Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway |
| Q90814281 | Regulation of aberrantly expressed SERPINH1 by antitumor miR-148a-5p inhibits cancer cell aggressiveness in gastric cancer |
| Q91622783 | Reproduction of molecular subtypes of gastric adenocarcinoma by transcriptome sequencing of archival tissue |
| Q92259805 | Resolution of Gastric Cancer-Promoting Inflammation: A Novel Strategy for Anti-cancer Therapy |
| Q92862205 | Risk factors predisposing to cardia gastric adenocarcinoma: Insights and new perspectives |
| Q91688483 | Role of Cancer-Associated Fibroblast in Gastric Cancer Progression and Resistance to Treatments |
| Q59340320 | SEPROGADIC - serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy |
| Q37688513 | SPARC expression in gastric cancer predicts poor prognosis: Results from a clinical cohort, pooled analysis and GSEA assay |
| Q47915753 | Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. |
| Q36400378 | Seom guidelines for the treatment of gastric cancer 2015. |
| Q57176429 | Significance of Preoperative Systemic Immune Score for Stage I Gastric Cancer Patients |
| Q92382425 | Significant function and research progress of biomarkers in gastric cancer |
| Q50107191 | Silencing of peroxiredoxin II by promoter methylation is necessary for the survival and migration of gastric cancer cells |
| Q90437168 | Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity |
| Q90636313 | Simvastatin Inhibits the Malignant Behaviors of Gastric Cancer Cells by Simultaneously Suppressing YAP and β-Catenin Signaling |
| Q38871189 | Single Center Experience on Anatomy-and Histopathology-Based Gastric Cancer Molecular Classification |
| Q61447416 | Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial |
| Q89721950 | Single-Cell Genomic Characterization Reveals the Cellular Reprogramming of the Gastric Tumor Microenvironment |
| Q91612580 | Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type |
| Q38776229 | Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers. |
| Q40192048 | Stratification of Digestive Cancers with Different Pathological Features and Survival Outcomes by MicroRNA Expression. |
| Q89535788 | Study on the mechanisms of compound Kushen injection for the treatment of gastric cancer based on network pharmacology |
| Q37362819 | Synergistic combination of DT-13 and topotecan inhibits human gastric cancer via myosin IIA-induced endocytosis of EGF receptor in vitro and in vivo |
| Q92073945 | Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening |
| Q97535476 | Systemic chemotherapy for gastro-oesophagogastric junction adenocarcinoma and stomach adenocarcinoma in a metastatic setting |
| Q55472607 | TIMP2 is a Poor Prognostic Factor and Predicts Metastatic Biological Behavior in Gastric Cancer. |
| Q91982116 | TRPV2 Calcium Channel Gene Expression and Outcomes in Gastric Cancer Patients: A Clinically Relevant Association |
| Q61818369 | TULP3: A potential biomarker in colorectal cancer? |
| Q38939088 | Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new? |
| Q41340207 | Targeted therapies for gastric cancer: failures and hopes from clinical trials |
| Q92349505 | Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy |
| Q93048955 | Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis |
| Q38741697 | Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall? |
| Q64230121 | Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon |
| Q38689450 | The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. |
| Q98771218 | The Better Survival of MSI Subtype Is Associated With the Oxidative Stress Related Pathways in Gastric Cancer |
| Q90672474 | The Impact of Long-term Exposure to Low Levels of Inorganic Arsenic on the Hypomethylation of SEPT9 Promoter in Epithelial-Mesenchymal Transformed Colorectal Cancer Cell Lines |
| Q33600436 | The Origins of Gastric Cancer From Gastric Stem Cells: Lessons From Mouse Models. |
| Q55618345 | The Pattern of Signatures in Gastric Cancer Prognosis. |
| Q57120826 | The Predictive Value of Epstein-Barr Virus-Positivity in Patients Undergoing Gastrectomy Followed by Adjuvant Chemotherapy |
| Q38710597 | The Profile of Serum microRNAs Predicts Prognosis for Resected Gastric Cancer Patients Receiving Platinum-Based Chemotherapy. |
| Q58762545 | The Thomsen-Friedenreich Antigen: A Highly Sensitive and Specific Predictor of Microsatellite Instability in Gastric Cancer |
| Q56890968 | The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors |
| Q37392801 | The anti-apoptotic and prognostic value of fibroblast growth factor 9 in gastric cancer |
| Q100428137 | The changing face of gastric cancer: epidemiologic trends and advances in novel therapies |
| Q89953553 | The era of laparoscopic surgery for gastric cancer: what is the present territory and what will be next? |
| Q28078788 | The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond |
| Q50105819 | The prognosis role of AJCC/UICC 8th edition staging system in gastric cancer, a retrospective analysis |
| Q46266500 | The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. |
| Q90087481 | The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma |
| Q33876785 | The significance of a nineteenth century definition in the era of genomics: linitis plastica. |
| Q53108021 | The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal of a new TSNM staging system. |
| Q91689801 | Three Biomarkers Predict Gastric Cancer Patients' Susceptibility To Fluorouracil-based Chemotherapy |
| Q58695226 | Towards precision medicine: linking genetic and cellular heterogeneity in gastric cancer |
| Q89967074 | Traditional Classification and Novel Subtyping Systems for Bladder Cancer |
| Q57211498 | Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes |
| Q59129137 | Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology |
| Q91730183 | Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction |
| Q26767920 | Translating gastric cancer genomics into targeted therapies |
| Q30239109 | Translating genomic profiling to gastrointestinal cancer treatment |
| Q33829437 | Tumor and serum gamma-glutamyl transpeptidase, new prognostic and molecular interpretation of an old biomarker in gastric cancer. |
| Q47728785 | Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. |
| Q89295006 | Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer |
| Q104073775 | Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer |
| Q92725623 | Upregulation of BCAM and its sense lncRNA BAN are associated with gastric cancer metastasis and poor prognosis |
| Q98289253 | Upregulation of COL8A1 indicates poor prognosis across human cancer types and promotes the proliferation of gastric cancer cells |
| Q37662125 | Validation of the Memorial Sloan Kettering Cancer Center nomogram to predict disease-specific survival in a Chinese gastric cancer population receiving postoperative chemoradiotherapy after an R0 resection |
| Q48218531 | Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study. |
| Q57159608 | What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives |
| Q64071483 | Whole-genome sequencing reveals novel tandem-duplication hotspots and a prognostic mutational signature in gastric cancer |
| Q38751688 | Winding back Wnt signalling: potential therapeutic targets for treating gastric cancers |
| Q53750080 | [Novel pharmaceutical treatment approaches for gastric cancer]. |
| Q38703593 | miR-551b regulates epithelial-mesenchymal transition and metastasis of gastric cancer by inhibiting ERBB4 expression |
| Q90598986 | piRNAs in Gastric Cancer: A New Approach Towards Translational Research |
Search more.